Skip to main content
Log in

The November 1995 Revised Australian Guidelines for the Economic Evaluation of Pharmaceuticals

  • Special Article
  • Revised Australian Pharmacoeconomic Guidelines
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

In November 1995, the revised Australian Guidelines for the Economic Evaluation of Pharmaceuticals (‘the Guidelines’) were published. The new document is to be seen as a measured bureaucratic response to the perceived shortcomings of the August 1992 document. The new document sets substantially more demanding and more rigorous evidentiary standards in the reporting of randomised clinical trialş and in the justification of the selected evaluation methodology. It also introduces the requirement for a trial— or efficacy—based preliminary economic evaluation, and it recognises the need. under certain circumstances. to model economic evaluations.

Although this document has an immediate appeal to those coming to pharmacoeconomic evaluations from a clinical perspective. the approach taken is unlikely to appeal either to economists (the Guidelines continue to discourage cost—benefit analysis) or to health system evaluators working in a competitive delivery environment (such as the US). The Guidelines. in a US environment. would be seen as not only unreasonable in their evidentiary demands and in the task imposed on evaluators. but limited in their failure to take an explicit modelling or system approach to therapy intervention evaluations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Department of Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian GovernmentPublishing Service, 1992

    Google Scholar 

  2. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa: CCOHTA, 1994

    Google Scholar 

  3. Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee (including major submissions involving economic analyses). Canberra: Australian Government Publishing Service, 1995 Nov

    Google Scholar 

  4. Drummond MF. The future of pharmacoeconomics. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinicaltrials. 2nd ed. Philadelphia: Lippincott—Raven Publishers, 1996: 1225–8

    Google Scholar 

  5. Langley PC. Cost—effectiveness profiles with an expanding treatment population. Clin Ther 1995; 17 (6): 1207–12

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Langley, P.C. The November 1995 Revised Australian Guidelines for the Economic Evaluation of Pharmaceuticals. Pharmacoeconomics 9, 341–352 (1996). https://doi.org/10.2165/00019053-199609040-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199609040-00007

Keywords

Navigation